TransCode Therapeutics reports encouraging results in preclinical glioblastoma trials with its main treatment, TTX-MC138

TransCode Therapeutics, Inc., a firm dedicated to efficiently treating cancer via RNA therapeutics, has reported positive findings with its primary treatment candidate, TTX-MC138, in mouse models with human glioblastoma multiforme tumors. The study showed successful delivery of the treatment candidate to the brain tumors and successful interaction with its intended target.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

GBM reigns as the most prevalent and ruthless type of brain malignancy. Despite advances in conventional treatment methods, the prognosis remains dismal. The rentention in the survival rate, essentially unaltered over the previous three decades, necessitates the urgency for TransCode to pioneer more potent therapies. TTX-MC138 was employed to treat GBM patients, with MRI imaging utilized to appraise the delivery of the therapeutic agent to the tumors.

Further, the pharmacodynamic action of TTX-MC138 was gleaned from the evaluation of miRNA-10b suppression, the therapeutic target, deploying qRT-PCR. Upon intravenous injection, TTX-MC138 congregated effectively in the tumors. Crucially, ongoing activity was exhibited by the therapeutic agent, which profoundly impeded miRNA-10b, recognized as a catalyst of tumor advancement in glioblastoma.

TTX-MC138 comprises of an iron oxide nanocarrier fused with a nucleic acid, deliberately tailored to repress the oncogenic RNA, miRNA-10b. MicroRNA-10b is characterized as the main controller of cancer progression in multiple developed solid tumors. TransCode surmises that TTX-MC138 holds potential as a remedial instrument against these cancers.

Application of TTX-MC138 has led to full remission of metastatic affections in diverse mouse models of pancreatic and breast tumors. Furthermore, TTX-MC138 demonstrated fruitful delivery and efficacy in spontaneous feline mammary carcinoma.

TransCode's CEO, Michael Dudley, asserted the in vivo delivery of TTX-MC138 in GBM tumors, bred from human tissue, fortifies former indications supporting the capacity of therapeutic contenders employing the TTX platform to conglomerate in tumor tissue, engaging RNA targets beyond the liver.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of October 1, 2023, there are 4 investigational drugs for the miR-10b target, including 7 indications, 6 R&D institutions involved, and as many as 774 patents.

TTX-MC-138 is aimed at miR-10b, presenting possible therapeutic uses in diverse cancer forms. Now at the onset of its first development phase, the said compound is categorized as an orphan drug, signifying its prospective capabilities in treating uncommon diseases or health issues. Additional investigative studies and clinical assessments are necessary to validate its harmlessness and potency.